InVirtuoLabs

Executive Summary

InVirtuoLabs is a Swiss biotechnology company founded in 2020 that integrates artificial intelligence, generative chemistry, and physics-based molecular simulations to revolutionize drug discovery. Its platform efficiently explores vast chemical spaces to identify and optimize novel drug candidates, aiming to accelerate the development of life-changing therapies. The company is currently in the pre-clinical stage, focusing on building its platform and validating its approach through internal programs or collaborations. With its unique combination of machine learning and molecular modeling, InVirtuoLabs positions itself to address key bottlenecks in early-stage drug discovery, such as hit identification and lead optimization, by reducing time and cost compared to traditional methods. The company is based in Lausanne, Switzerland, a hub for biotech innovation, and is privately held with no disclosed funding or valuation data.

Upcoming Catalysts (preview)

• Q4 2026Pharmaceutical Partnership or Collaboration40% success
• Q2 2027Series A Funding Round50% success
• TBDPreclinical Proof-of-Concept Data for Lead Program35% success